Founded in April 2010, HistoIndex® is a leading global MedTech spin-off company from the Institute of Biotechnology and Nanotechnology (IBN), Agency of Science, Technology and Research (A*STAR), Singapore. The company specializes in AI-based stain-free digital pathology solutions. Enabled by Second Harmonic Generation (SHG) and Two-Photon Excitation (TPE), along with automated imaging analysis, HistoIndex's digital pathology platform characterizes and accurately quantifies fibrosis, steatosis, inflammation and ballooning; including fine measurements of disease progression and regression.
Our focus is on the accurate assessment of nonalcoholic steatohepatitis (NASH), a silent chronic liver disease that is linked to unhealthy lifestyles and metabolic syndromes. NASH faces a huge unmet medical need in our world today, and is expected to become the biggest cause of liver transplants by 2020.
Critical for the evaluation of treatment efficacy, this SHG-enabled digital pathology platform is currently utilized in multiple NASH and Hepatitis B FDA clinical trials, and has assisted many organizations in fully quantifying histological changes in their preclinical studies and clinical trials. To date, more than 150 hospitals, universities, research institutes, CROs and drug development companies all over the world have benefited from HistoIndex's comprehensive suite of premium imaging solutions.